Vortioxetine not checked
Takeda · H. Lundbeck A/S · Lu AA21004
FollowEvery change as it happens, and a Monday email
Trials
4 active
14 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Major Depressive Disorder
- Main trialPhase 3
- “The main aim of the study is to check how well vortioxetine 10 mg/day or 20 mg/day works and to check for side effects compared to a placebo on depression symptoms in Japanese teenagers aged 12 to 17 years with a diagnosis of Major Depressive Disorder (MDD). The overall time each participant will be in the study is about 20 weeks. This includes up to 15 days (about 2 weeks) to check who can take part, a 14-week period where everyone receives vortioxetine or a placebo, and after that, a 4-week period to check for any side effects after treatment. During the study, participants will visit…”In the company’s words, NCT07204314 on ClinicalTrials.gov
- Other names
- Lu AA21004 · Brintellix · Trintellix
Other drugs for Major Depressive Disorder
- SeltorexantJohnson & Johnson (Janssen) · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- CYB003Cybin IRL Limited · Phase 3
- Mitizodone PhosphateSunshine Lake Pharma Co., Ltd. · Phase 2/3
- OsavampatorNeurocrine Biosciences · Phase 3
Coming up1
- 30 Sep 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials14
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Sep 2029 | A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder | |
| Phase 4Completed | 1 Mar 2019 | Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD) | |
| Phase 4Completed | 9 Mar 2021 | Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD) | |
| Phase 4Completed | 6 Jan 2022 | Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression | |
| Phase 4Completed | 11 Feb 2022 | Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India | |
| Phase 4Completed | 6 Jul 2022 | Vortioxetine in Patients With Depression and Early Dementia | |
| Phase 3Completed | 16 Mar 2018 | A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder | |
| Phase 3Completed | 16 Apr 2020 | Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age | |
| Phase 3Completed | 21 Jan 2022 | Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD) | |
| Phase 3Terminated | 25 Mar 2022 | Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age | |
| Phase 3Terminated | 31 Mar 2022 | Vortioxetine to Prevent Return of Symptoms in Children With Depression | |
| Phase 4Authorised | not given | "SAFE DISCONTINUATION OF ANTIDEPRESSANTS IN INDIVIDUALS WITH CLINICALLY REMITTED DEPRESSIVE DISORDERS" | |
| Phase 2/3Authorised | not given | Cognitive effects of adjuntive Vortioxetine in early Schizophrenia | |
| Phase 4Authorised | not given | A multicenter randomized, controlled, single-blind, adaptive phase IV clinical trial to evaluate the efficiency and effectiveness of a pre-emptive pharmacogenetic strategy for antidepressant selection in patients with depressive disorder: The PREDICT adaptive clinical trial. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026